Cargando…

A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes

BACKGROUND/OBJECTIVES: Patients referred for HNF1B testing present very heterogeneous phenotypes. Despite suggestive characteristics, many do not harbor mutations in HNF1B. Our objective was to evaluate the clinical characteristics of probands referred for HNF1B genetic testing through a nationwide...

Descripción completa

Detalles Bibliográficos
Autores principales: Sztromwasser, Paweł, Michalak, Arkadiusz, Małachowska, Beata, Młudzik, Paulina, Antosik, Karolina, Hogendorf, Anna, Zmysłowska, Agnieszka, Borowiec, Maciej, Młynarski, Wojciech, Fendler, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons A/S 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217165/
https://www.ncbi.nlm.nih.gov/pubmed/31825128
http://dx.doi.org/10.1111/pedi.12959
_version_ 1783532559784738816
author Sztromwasser, Paweł
Michalak, Arkadiusz
Małachowska, Beata
Młudzik, Paulina
Antosik, Karolina
Hogendorf, Anna
Zmysłowska, Agnieszka
Borowiec, Maciej
Młynarski, Wojciech
Fendler, Wojciech
author_facet Sztromwasser, Paweł
Michalak, Arkadiusz
Małachowska, Beata
Młudzik, Paulina
Antosik, Karolina
Hogendorf, Anna
Zmysłowska, Agnieszka
Borowiec, Maciej
Młynarski, Wojciech
Fendler, Wojciech
author_sort Sztromwasser, Paweł
collection PubMed
description BACKGROUND/OBJECTIVES: Patients referred for HNF1B testing present very heterogeneous phenotypes. Despite suggestive characteristics, many do not harbor mutations in HNF1B. Our objective was to evaluate the clinical characteristics of probands referred for HNF1B genetic testing through a nationwide monogenic diabetes screening program. METHODS: Probands tested for HNF1B mutations in the 2005‐2018 period (N = 50) were identified in the Polish Monogenic Diabetes Registry, which prospectively recruits primarily pediatric patients and their families on a nationwide scale. Variants that had been reported pathogenic were reassessed using criteria of the American College of Medical Genetics and Genomics (ACMG). A structured medical interview was performed with all available individuals, their parents, and/or their physicians. For each patient, HNF1B score was calculated based on available clinical information. RESULTS: The study group numbered 36 unrelated probands (28% lost to follow‐up): 14 with pathogenic or likely‐pathogenic variants in HNF1B, one with a variant of uncertain significance, and 21 negative for HNF1B mutations. Presence of cystic kidneys (OR = 9.17, 95% CI:1.87‐44.92), pancreatic abnormalities (OR = 15, 95% CI:1.55‐145.23), elevated liver enzymes (OR = 15, 95% CI:1.55‐145.23) best discriminated HNF1B‐positive cases from the negative ones. Presence of impaired glucose tolerance coupled with kidney disease in the proband and one parent was also highly predictive for HNF1B mutations (OR = 11.11, 95% CI:1.13‐109.36). HNF1B‐score with recommended cutoff distinguished patients with and without HNF1B findings with 100% sensitivity and 47.6% specificity. Addition of four clinical variables to select patients based on HNF1B score improved specificity to 71.4% (95% CI:47.8%‐88.7%) while retaining 100% sensitivity. CONCLUSIONS: Detailed medical interview may enable more accurate patient selection for targeted genetic testing.
format Online
Article
Text
id pubmed-7217165
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons A/S
record_format MEDLINE/PubMed
spelling pubmed-72171652020-05-13 A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes Sztromwasser, Paweł Michalak, Arkadiusz Małachowska, Beata Młudzik, Paulina Antosik, Karolina Hogendorf, Anna Zmysłowska, Agnieszka Borowiec, Maciej Młynarski, Wojciech Fendler, Wojciech Pediatr Diabetes Monogenic Diabetes and Other Genetic Disorders of Glucose Metabolism BACKGROUND/OBJECTIVES: Patients referred for HNF1B testing present very heterogeneous phenotypes. Despite suggestive characteristics, many do not harbor mutations in HNF1B. Our objective was to evaluate the clinical characteristics of probands referred for HNF1B genetic testing through a nationwide monogenic diabetes screening program. METHODS: Probands tested for HNF1B mutations in the 2005‐2018 period (N = 50) were identified in the Polish Monogenic Diabetes Registry, which prospectively recruits primarily pediatric patients and their families on a nationwide scale. Variants that had been reported pathogenic were reassessed using criteria of the American College of Medical Genetics and Genomics (ACMG). A structured medical interview was performed with all available individuals, their parents, and/or their physicians. For each patient, HNF1B score was calculated based on available clinical information. RESULTS: The study group numbered 36 unrelated probands (28% lost to follow‐up): 14 with pathogenic or likely‐pathogenic variants in HNF1B, one with a variant of uncertain significance, and 21 negative for HNF1B mutations. Presence of cystic kidneys (OR = 9.17, 95% CI:1.87‐44.92), pancreatic abnormalities (OR = 15, 95% CI:1.55‐145.23), elevated liver enzymes (OR = 15, 95% CI:1.55‐145.23) best discriminated HNF1B‐positive cases from the negative ones. Presence of impaired glucose tolerance coupled with kidney disease in the proband and one parent was also highly predictive for HNF1B mutations (OR = 11.11, 95% CI:1.13‐109.36). HNF1B‐score with recommended cutoff distinguished patients with and without HNF1B findings with 100% sensitivity and 47.6% specificity. Addition of four clinical variables to select patients based on HNF1B score improved specificity to 71.4% (95% CI:47.8%‐88.7%) while retaining 100% sensitivity. CONCLUSIONS: Detailed medical interview may enable more accurate patient selection for targeted genetic testing. John Wiley & Sons A/S 2020-01-29 2020-05 /pmc/articles/PMC7217165/ /pubmed/31825128 http://dx.doi.org/10.1111/pedi.12959 Text en © 2019 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Monogenic Diabetes and Other Genetic Disorders of Glucose Metabolism
Sztromwasser, Paweł
Michalak, Arkadiusz
Małachowska, Beata
Młudzik, Paulina
Antosik, Karolina
Hogendorf, Anna
Zmysłowska, Agnieszka
Borowiec, Maciej
Młynarski, Wojciech
Fendler, Wojciech
A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
title A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
title_full A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
title_fullStr A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
title_full_unstemmed A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
title_short A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
title_sort cross‐sectional study of patients referred for hnf1b‐mody genetic testing due to cystic kidneys and diabetes
topic Monogenic Diabetes and Other Genetic Disorders of Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217165/
https://www.ncbi.nlm.nih.gov/pubmed/31825128
http://dx.doi.org/10.1111/pedi.12959
work_keys_str_mv AT sztromwasserpaweł acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT michalakarkadiusz acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT małachowskabeata acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT młudzikpaulina acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT antosikkarolina acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT hogendorfanna acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT zmysłowskaagnieszka acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT borowiecmaciej acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT młynarskiwojciech acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT fendlerwojciech acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT sztromwasserpaweł crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT michalakarkadiusz crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT małachowskabeata crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT młudzikpaulina crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT antosikkarolina crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT hogendorfanna crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT zmysłowskaagnieszka crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT borowiecmaciej crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT młynarskiwojciech crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes
AT fendlerwojciech crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes